Second Primary Tumors and Immune Phenomena After Fludarabine or 2-Chloro-2′-Deoxy adenosine Treatment

References

• Cheson B. D. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 1995; 13: 2431–2439
   PubMed Web of Science ®Google Scholar
• Plunkett W., Gandhi V. Nucleoside analogs: cellular phamacology, mechanisms of action, and strategies for combination therapies. Nucleoside analogs in cancer therapy, B.D. Cheson, M.J. Keating, W. Plunkett. Marcel Dekker, New York 1997; 1–35
   Google Scholar
• Van Den Neste E., Delannoy A., Vandercam B., Bosly A., Ferrant A., Mineur P., Montfort L., Martiat P., Streatmans N., Filleul B., Michaux J. L. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. 1996; 56: 235–240
   PubMed Web of Science ®Google Scholar
• Anaissie E. J., Kontoyiannis D. P., O'Brien S., Kantarjian H., Robertson L., Lerner S., Keating M. J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med. 1998; 129: 559–566
   PubMed Web of Science ®Google Scholar
• Zulian G. B., Roux E., Tiercy J. M., Extermann M., Diebold-Berger S., Reymond J.-M., Helg C., Zubler R., Betticher D. C., Alberto P., Jeannet M., Chapuis B. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br. J. Haematol. 1995; 89: 83–89
   PubMed Web of Science ®Google Scholar
• Maung Z. T., Wood A. C., Jackson G. H., Turner G. E., Appleton A. L., Hamilton P. J. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br. J. Haematol. 1994; 88: 649–652
   PubMed Web of Science ®Google Scholar
• Sandoval A., Consoli U., Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin. Cancer Res. 1996; 2: 1731–1741
   PubMed Web of Science ®Google Scholar
• Kuwabara M., Tanabe K., Hiraoka W., Tamura Y., Sato F., Matsuda A., Ueda T. 2-chlorodeoxyadenosine inhibits the repair of DNA double-strand breaks in X-irradiated Chinese hamster V79 cells. Chem.-Biol. Interactions 1991; 79: 349–358
   PubMed Web of Science ®Google Scholar
• Huang P., Siciliano M. J., Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleotides. Mutat. Res. 1989; 210: 291–301
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P., Larsen S. O., Andersson M., Daugaard G., Ersbøll J., Hansen S. W., Hou-Jensen K., Nielsen D., Sigsgaard T. C., Specht L., Østerlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975–1986
   PubMed Web of Science ®Google Scholar
• Levine A. M. AIDS-related malignancies: the emerging epidemics. J. Natl. Cancer Inst. 1993; 85: 1382–1397
   PubMed Web of Science ®Google Scholar
• Ellis D., Jaffe R., Green M., Janosky J. J., Lombardozzi-Lane S., Shapiro R., Scantlebury V., Vivas C., Jordan M. L. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68: 997–1003
   PubMed Web of Science ®Google Scholar
• Krishnan K., Adams P., Silveira S., Sheldon S., Dabich L. Therapy-related acute myeloid leukaemia following immunosuppression with azathioprine for polymyositis. Clin. Lab. Haematol. 1994; 16: 285–289
   PubMedGoogle Scholar
• Travis L. B., Curtis R. E., Hankey B. F., Fraumeni J. F. Second cancers in patients with chronic lymphocytic leukemia. J Natl. Cancer Inst. 1992; 84: 1422–1427
   PubMed Web of Science ®Google Scholar
• Ellis M., Lishner M. Second malignancies following treatment in non-Hodgkin's lymphoma. Leuk. Lymph. 1993; 9: 337–342
   PubMed Web of Science ®Google Scholar
• Mauro F. R., Foa R., Giannarelli D., Cordone I., Crescenzi S., Pescarmona E., Sala R., Cerretti R., Mandelli F. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94: 448–454
   PubMed Web of Science ®Google Scholar
• Dighiero G., Maloum K., Desablens B., Cazin B., Navarro M., Leblay R., Leporrier M., Jaubert J., Lepeu G., Dreyfus B., Binet J.-L., Travade P. Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. J. Med. 1998; 338: 1506–1514
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Vena D. A., Barett J., Freidlin B. Second malignancies as a consequence of nucleoside analogs therapy for chronic lymphoid leukemias. J. Clin. Oncol. 1999; 17: 2454–2460
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Strom S. S., Estey E., O'Brien S., Keating M. J., Jiang H., Adams T., Talpaz M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J. Clin. Oncol. 1997; 15: 1803–1810
   PubMed Web of Science ®Google Scholar
• Au W. Y., Klasa R. J., Gallagher R., Le N., Gascoyne R., Connors J. M. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998; 92: 1160–1164
   PubMed Web of Science ®Google Scholar
• Saven A., Burian C., Koziol J. A., Piro L. D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–1926
   PubMed Web of Science ®Google Scholar
• Keating M. J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Roller C., Beran M., Freireich E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
   PubMed Web of Science ®Google Scholar
• Keating M. J., O'Brien S., Lerner S., Roller C., Beran M., Robertson L. E., Freireich E. J., Estey E., Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) treated with fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171
   PubMed Web of Science ®Google Scholar
• Flynn J. M., Howard R. S., Byrd J. C. Secondary malignancies in B-cell chronic lymphocytic leukemia (CLL): association with CLL but no additional impact with fludarabine or alkylator treatment. Bloob 1999; 94((suppl. 1))298b, (abstract 4553)
   Google Scholar
• Kraut E. H., Grever M. R., Bouroncle B. A. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994; 84: 4061–4063
   PubMed Web of Science ®Google Scholar
• Robak T., Blasinska-Morawiec M., Blonski J., Hellmann A., Halaburda K., Konopka L., Kotlarek-Haus S., Potoczek S., Hansz J., Dmoszynska A., Urasinski I., Zdziarska B., Dwilewicz-Trojaczek J., Holowiecki J., Skotnicki A. B. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur. J. Haematol. 1999; 62: 49–56
   PubMed Web of Science ®Google Scholar
• Robak T., Blonski J. Z., Urbanska-Rys H., Blasinska-Morawiec M., Skotnicki A. B. 2-Chlorodeoxyad-enosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13: 518–523
   PubMed Web of Science ®Google Scholar
• Schlaifer D., Rigal-Huguet F., Pris J., Brousset P., Delannoy A., Bosly A. Secondary neoplasms in two patients treated with purine analogs. Nouv. Rev. Fr. Hematol. 1994; 36: 341
   PubMedGoogle Scholar
• Wijermans P. W., van Groningen K., van Royen E. A., Bruijn J. A. Kaposi's sarcoma in an HIV-negative patient as the cause of thrombocytopenia. Ann. Hematol. 1994; 68: 307–310
   PubMed Web of Science ®Google Scholar
• Davidovitz Y., Ballin A., Meytes D. Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia. Acta Haematol. 1997; 98: 44–46
   PubMed Web of Science ®Google Scholar
• Palomera L., Azaceta G., Varo M. J., Soria J., Gutierrez M. Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. Haematologica 1998; 83: 1045–1046
   PubMed Web of Science ®Google Scholar
• Lauria F., Rondelli D., Zinzani P. L., Bocchia M., Marotta G., Salvucci M., Raspadori D., Ventura M. A., Birtolo S., Forconi F., Tura S. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997; 11: 629–632
   PubMed Web of Science ®Google Scholar
• Bilgeri R., Petzer A. L., Zilian U., Geisen F. H., Schirmer M., Haun M., Konwalinka G. Effect of deoxycyti-dine on 2-chloro-deoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells. Exp. Hematol. 1993; 21: 432–437
   PubMed Web of Science ®Google Scholar
• Orchard J. A., Bolam S., Oscier D. G. Association of myelodysplastic changes with purine analogs. Br. J. Haematol. 1998; 100: 677–679
   PubMed Web of Science ®Google Scholar
• Van Den Neste E., Louviaux I., Michaux J.-L., Delannoy A., Michaux L., Hagemeijer A., Scheiff J.-M., Bosly A., Straetmans N., Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br. J. Haematol. 1999; 105: 268–270
   PubMed Web of Science ®Google Scholar
• Kong L. R., Huang C.-F., Hakimian D., Variakojis D., Klein L., Kuzel T. M., Gordon L. I., Zanzig C., Wollins E., Tallman M. S. Long term follow-up and late complications of 2-Chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Cancer 1998; 82: 957–964
   PubMed Web of Science ®Google Scholar
• Laurencet F. M., Zulian G. B., Cabrol C., Betticher D. Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy. Cancer Genet. Cytogenet 1997; 99: 85–89
   PubMed Web of Science ®Google Scholar
• Frewin R. J., Provan D., Smith A. G. Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia. Clin. Lab. Haem. 1997; 19: 151–152
   PubMedGoogle Scholar
• Kroft S. H., Tallman M. S., Shaw J. M., Thangavelu M., Peterson L. C. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyad-enosine (2-CdA). Leukemia 1997; 11: 170
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Estey E., Kantarjian H., Roller C., O'Brien S., Brown H., Keating M. J. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 1994; 8: 2047–2051
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Zucca E., von Rohr A., Egger T., Radford J. A., Ambrosetti A., Bürki K., Rufener B., Hsu Schmitz S. F., Cerny T. 2-chlorodeoxyadenosine (2-CdA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann. Oncol. 1996; 7: 793–799
   PubMed Web of Science ®Google Scholar
• Coso D., Costello R., Cohen-Valensi R., Sainty D., Nezri M., Gastaut J. A., Bouabdallah R. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann. Oncol. 1999; 10: 362–363
   PubMed Web of Science ®Google Scholar
• Morrison V. A., Rai K. R., Peterson B. L., Kolitz J. E., Elias L., Hines J. D., Sheperd L., Larson R. A., Schiffer C. A. Transformation to Richter's syndrome or prolymphocyte leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL): an intergroup stucy (CALGB 9011). Blood 1999; 94((Suppl. 1))539a, (abstract 2410)
   PubMed Web of Science ®Google Scholar
• Fridrik M. A., Jäger G., Kienzer H. R., Hausmanninger H., Oppitz P., Krieger O., Zabernigg A., Lang A., Neubauer M., Weidinger G., Schiller L., Seewan H. L., Ghott A., Linkesch W. Efficacy and toxicity of 2-chlorodeoxy-adenosine (Cladribine) -2 h infusion for 5 days-as first-line treatment for advanced low grade non-Hodgkin's lymphoma. Eur. J. Cancer 1998; 34: 1560–1564
   PubMed Web of Science ®Google Scholar
• Beutler E., Piro L. D., Saven A. 2-chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk. Lymphoma 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Shields D. J., Byrd J. C., Abbondanzo S. L., Lichy J. H., Diehl L. F., Aguilera N. I. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Mod. Pathol. 1997; 10: 1151–1159
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Flandrin G., Tricot G., Brouet J. C., Seligmann M., Bernard J. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders (Richter's syndrome: A study of 25 cases). Cancer 1981; 48: 1302–1308
   PubMed Web of Science ®Google Scholar
• Desablens B., Garidi R., Fernandes J., Capiod J.-C., Legrand S., Desablens B., Tabuteau S. Does fludarabine (FAMP) increase the risk of Richter's syndrome (RS) among chronic lymphocytic leukaemia?. Haematologica 1999; 84: 259, (abstract 1093)
   Google Scholar
• Pocock C., Matutes E., Wotherspoon A., Cunningham D., Catovsky D. Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma. Blood 1998; 92((Suppl. 1))429a, (abstract 1774)
   Google Scholar
• Giles F. J., O'Brien S. M., Keating M. J. Chronic lymphocytic leukemia in (Richter's) transformation. Semin. Oncol. 1998; 25: 117–125
   PubMed Web of Science ®Google Scholar
• Fayad L., Robertson L. E., O'Brien S., Manning J. T., Wright S., Hagemeister F., Cabanillas F., Keating M. J. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk. Lymphoma 1996; 23: 333–337
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Orlandi E., Baldanti F., Furione M., Pagnucco G., Astori C., Arcaini L., Viglio A., Paulli M., Gerna G., Bernasconi C. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br. J. Haematol. 1999; 107: 877–882
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Li C. Y., Lloyd R. V., Phyliky R. L. Epstein-Barr virus infection in Richter's transformation. Am. J. Pathol. 1999; 60: 99–104
   Web of Science ®Google Scholar
• Niesvizky R., Zhu A. X., Louie D., Michaeli J. Epstein-Barr virus associated lymphoma after treatment of macroglobulinemia with cladribine. N. Engl. J. Med. 1999; 341: 55
   PubMed Web of Science ®Google Scholar
• Romine J. S., Sipe J. C., Koziol J. A., Zyroff J., Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 1999; 111: 35–44
   PubMedGoogle Scholar
• Davis J. C., Austin H., Boumpas D., Fleishner T. A., Yarboro C., Larson A., Balow J., Klippel J. H., Scott D. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosous-associated glomerulonephritis. Arthritis Rheum. 1998; 41: 335–343
   PubMed Web of Science ®Google Scholar
• Adams E. M., Pucino E., Yarboro C., Hicks J. E., Thornton B., McGarvey C., Sonies B. C., Bartlett M. L., Villalba M. L., Fleisher T., Plotz P. H. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J. Rheumatol. 1999; 26: 352–360
   PubMed Web of Science ®Google Scholar
• Boumpas D. T., Tassulias I. O., Fleisher T. A., Vaughan E., Piscitelli S., Kim Y., Pucino F., Balow J. E., Austin H. A. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol. 1999; 52: 67–75
   PubMed Web of Science ®Google Scholar
• Davis J. C., Fessler B. J., Tassiulas I. O., McInnes I. B., Yarboro C. H., Pillemer S., Wilder R., Fleishner T. A., Klippel J. H., Boumpas D. T. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J. Rheumatol. 1998; 25: 1694–1704
   PubMed Web of Science ®Google Scholar
• Di Raimondo F., Giustolisi R., Cacciola E., O'Brien S., Kantarjian H., Robertson L. B., Keating M. J. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk. Lymphoma 1993; 11: 63–68
   PubMed Web of Science ®Google Scholar
• Robak T., Blasinska-Morawiec M., Krykowski E., Hellman A., Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine. Eur. J. Haematol 1997; 58: 109–113
   PubMed Web of Science ®Google Scholar
• Blanche P., Bouscary D., Gombert B., Stieltjes N., Dreyfus F., Sicard D. Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia. Leukemia 1999; 13: 1294
   PubMed Web of Science ®Google Scholar
• Serra S., Real E., Pastor E., Grau E. Refractory pure red-cell aplasia associated with B chronic lymphocytic leukemia successfully treated by fludarabine. Haematologica 1999; 84: 1154–1155
   PubMed Web of Science ®Google Scholar
• Ribeiro I., Tsatalas C., Catovsky D. Treatment of red cell aplasia in CLL with fludarabine. Leukemia 1999; 13: 1897
   PubMed Web of Science ®Google Scholar
• Lewis F. B., Schwartz R. S., Dameshek W. X-irradiation and alkylating agents as possible “trigger” mechanisms in the autoimmune complications of malignant lymphoproliferative diseases. Clin. Exp. Immunol. 1966; 1: 3–11
   PubMedGoogle Scholar
• Orchard J., Bolam S., Myint H., Oscier D. G., Hamblin T. In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br. J. Haematol. 1998; 102: 1112–1113
   PubMed Web of Science ®Google Scholar
• Otton S. H., Turner D. L., Frewin R., Davies S. V., Johnson S. A. Autoimmune thrombocytopenia after treatment with campath 1H in a patient with chronic lymphocytic leukemia. Br. J. Haematol. 1999; 106: 261–262
   PubMed Web of Science ®Google Scholar
• Stern S. C.M., Shah S., Costello C. Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia. Br. J. Haematol. 1999; 106: 833–839
   PubMed Web of Science ®Google Scholar
• Chasty R. C., Myint H., Oscier D. G., Orchard J. A., Bussutil D. P., Hamon M. D., Prentice A. G., Copplestone J. A. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CdA). Leuk. Lymphoma 1998; 29: 391–398
   PubMed Web of Science ®Google Scholar
• Sen K., Kalaycio M. Evan's syndrome precipitated by fludarabine therapy in a case of CLL. Am. J. Haematol. 1999; 61: 219
   PubMed Web of Science ®Google Scholar
• Shvidel L., Shtarlid M., Klepfish A., Sigler E., Berrebi A. Evans syndrome complicating fludarabine treatment for advanced B-CLL. Br. J. Haematol. 1997; 99: 706
   PubMed Web of Science ®Google Scholar
• Bay J. O., Fouassier M., Béal D., Alcaraz L., Cure H., Chollet P., Plagne R., Travade P. Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia. Hematol. Cell. The. 1997; 39: 209–212
   PubMedGoogle Scholar
• Montillo M., Tedeschi A., Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk. Lymphoma 1994; 15: 187–188
   PubMed Web of Science ®Google Scholar
• Weiss R. B., Freiman J., Kweder S. L., Diehl L. F., Byrd J. C. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 1998; 16: 1885–1889
   PubMed Web of Science ®Google Scholar
• Vick D. J., Byrd J.C, Beal C. L., Chaffin D. L. Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma. Vox Sang. 1998; 74: 122–126
   PubMed Web of Science ®Google Scholar
• Gonzalez H., Leblond V., Azar N., Sutton L., Gabarre J., Binet J.-L., Vernant J.-R, Dighiero G. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol. Cell. Ther. 1998; 40: 113–118
   PubMedGoogle Scholar
• Myint H., Copplestone J. A., Orchard J., Graig V., Curtis D., Prentice A. G., Hamon M. D., Oscier D. G., Hamblin T. J. Fludarabine-related autoimmune hemolytic anaemia in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 1995; 91: 341–344
   PubMed Web of Science ®Google Scholar
• The French Cooperative group on CLL, Johnson S., Smith A. G., Loftier H., Ösby E., Gunnar J., Emmerich B., Wyld P. J., Hiddeman P. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438
   PubMed Web of Science ®Google Scholar
• Maclean R., Meiklejohn D., Soutar R. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 1996; 92: 768–769
   PubMed Web of Science ®Google Scholar
• Sezer O., Schmid P., Hallek M., Schweigert M., Beinert T., Langelotz C., Mergenthaler H. G., Possinger K. Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia. Ann. Hematol. 1999; 78: 475–477
   PubMed Web of Science ®Google Scholar
• Lärfars G., Udén-Blohmé A.-M., Samuelson J. Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies. Br. J. Haematol. 1996; 94: 709–712
   PubMed Web of Science ®Google Scholar
• Rutella S., Sica S., Rumi C., Martucci R., Etuk B., de Stefano V., Testa G., Leone G., Peschle C. Hypereosinophilia during 2-chlorodeoxyadenosine treatment for hairy cell leukemia. Br. J. Haematol. 1996; 92: 426–428
   PubMed Web of Science ®Google Scholar
• Robak T., Blasinska-Morawiec M., Krykowski E., Hellman A., Lewandowski K., Dmoszynska A., Adamczyk-Cioch M., Kazimierczak M., Trepinska E., Dwilewicz-Trojaczek M., Kuratowska Z., Skotnicki A. B., Nowak W. S., Zdziarska B., Urasinski I. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patinets with lymphoproliferative diseases. Eur. J. Haematol. 1997; 59: 216–220
   PubMed Web of Science ®Google Scholar
• Meunier P., Castaigne S., Bastie J.-N., Chosidow O., Aractingi S. Cutaneous reactions after treatment with 2-Chlorodeoxyadenosine. Acta Derm. Venereal. 1996; 76: 385–386
   PubMed Web of Science ®Google Scholar
• Bazarbachi A., Bachelez H., Dehen L., Delmer L., Zittoun R., Dubertret L. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukemia. Ann. Oncol. 1995; 6: 730–731
   PubMed Web of Science ®Google Scholar
• Braess J., Reich K., Willert S., Strutz F., Neumann C., Hiddeman W., Wörmann B. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type. Ann. Hematol. 1997; 75: 227–230
   PubMed Web of Science ®Google Scholar
• Kane G. C., McMichael A. J., Patrick H., Erslev A. J. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate. Respir. Med. 1992; 86: 261–263
   PubMed Web of Science ®Google Scholar
• Levin M., Aziz M., Opitz L. Steroid-responsive interstitial pneumonitis after fludarabine therapy. Chest 1997; 111: 1472–1473
   PubMed Web of Science ®Google Scholar
• Hurst P. G., Habib M. P., Garewal H., Bluestein M., Paquin M., Greenberg B. R. Pulmonary toxicity associated with fludarabine monophosphate. Invest. New Drugs 1987; 5: 207–210
   PubMed Web of Science ®Google Scholar
• Cervantes F., Salgado C., Montserrat E., Rozman C. Fludarabine for prolymphocyte leukaemia and risk of interstitial pneumonitis. Lancet 1991; 336: 1130
   Web of Science ®Google Scholar
• Tisler A., Pierratos A., Lipton J. H. Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia. Nephrol. Dial. Transplant 1996; 11: 2306–2308
   PubMed Web of Science ®Google Scholar
• Timuragaoglu A., Karadogan I., Ündar L. Irreversible renal failure in a patient with chronic lymphocytic leukemia treated with fludarabine. Ann. Hematol. 1999; 78: 109–110
   PubMed Web of Science ®Google Scholar
• Macheta M. P., Parapia L. AL, Goulesbrough D. R. Renal failure in a patient with chronic lymphocytic leukemia treated with fludarabine. J. Clin. Pathol. 1995; 48: 181–182
   PubMed Web of Science ®Google Scholar
• Houssiau F. A., Delannoy A., Devogelaer J.-P. Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. Arthritis Rheum. 1998; 41: 1704–1705
   PubMed Web of Science ®Google Scholar
• Warzocha K., Krykowski E., Gora-Tybor J., Fronczak A., Robak T. Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Leuk. Lymphoma 1996; 21: 343–346
   PubMed Web of Science ®Google Scholar